menu
    • menu
    [{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Whitehawk Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Divestment","leadProduct":"Sirolimus Protein-bound Particle","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kaken Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"Betahistine Dimesilate","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Kaken Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"CymaBay Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Seladelpar Lysine","moa":"PPA-delta receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Kaken Pharmaceuticals","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.16,"dosageForm":"Capsule","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Alumis","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Kaken Pharmaceuticals","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.17999999999999999,"dosageForm":"Tablet","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"KalVista Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kaken Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Spruce Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Numab Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NM26-2198","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Numab Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"NM26-2198","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kaken Pharmaceuticals \/ Fresh Tracks Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Kaken Pharmaceuticals \/ Fresh Tracks Therapeutics"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Numab Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"ND081","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"KP-723","moa":"STAT6","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kaken Pharmaceuticals","amount2":1.25,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":1.25,"dosageForm":"Undisclosed","sponsorNew":"Kaken Pharmaceuticals \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Kaken Pharmaceuticals \/ Johnson & Johnson"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"bitBiome","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Astria Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kaken Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Kaken Pharmaceuticals

    Menu

    Kaken Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Navenibart

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : Astria Therapeutics

                            Deal Size : $32.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Astria Enters into Licensing Agreement with Kaken to Develop Navenibart for HAE in Japan

                            Details : Under the licensing agreement, Kaken will hold the rights of STAR-0215 (navenibart) in Japan. It is being evaluated in the late-stage for the treatment of hereditary angioedema.

                            Product Name : STAR-0215

                            Product Type : Antibody

                            Upfront Cash : $16.0 million

                            August 06, 2025

                            Lead Product(s) : Navenibart

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : Astria Therapeutics

                            Deal Size : $32.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sebetralstat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : KalVista Pharmaceuticals

                            Deal Size : $22.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            KalVista Licenses Sebetralstat to Kaken for HAE Market in Japan

                            Details : Under the licensing agreement, Kaken will holds the rights of KVD900 (sebetralstat) in Japan. It is being evaluated for the treatment of hereditary angioedema.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $11.0 million

                            April 08, 2025

                            Lead Product(s) : Sebetralstat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : KalVista Pharmaceuticals

                            Deal Size : $22.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus Protein-bound Particle

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Whitehawk Therapeutics

                            Deal Size : $100.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Whitehawk Finalizes Aadi Sale To Kaken In Strategic Transformation

                            Details : Through the divestment, Kaken assumes ownership of FYARRO (sirolimus protein-bound particles for injectable suspension) used to treat adults with malignant perivascular epithelioid cell tumor.

                            Product Name : Fyarro

                            Product Type : Antibiotic

                            Upfront Cash : $100.0 million

                            March 26, 2025

                            Lead Product(s) : Sirolimus Protein-bound Particle

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Whitehawk Therapeutics

                            Deal Size : $100.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ESK-001

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Recipient : Alumis

                            Deal Size : $180.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Alumis, Kaken Partner on ESK-001 for Dermatology in Japan

                            Details : The collaboration aims to develop, manufacture and commercialize ESK-001, a highly selective, next-gen oral TYK2 inhibitor, for dermatology indications in Japan.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $40.0 million

                            March 25, 2025

                            Lead Product(s) : ESK-001

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Recipient : Alumis

                            Deal Size : $180.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KP-723

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Johnson & Johnson

                            Deal Size : $1,247.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Kaken, J&J Ink Potential $1.2B-Plus STAT6 Deal

                            Details : Johnson gains an exclusive license to Kaken’s STAT6 program, including lead candidate KP-723, a preclinical STAT6 inhibitor, for autoimmune and allergic diseases, including atopic dermatitis.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $30.0 million

                            December 26, 2024

                            Lead Product(s) : KP-723

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Johnson & Johnson

                            Deal Size : $1,247.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ND081

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Recipient : Numab Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Numab and Kaken Collaborate On ND081 for Inflammatory Bowel Disease

                            Details : The collaboration aims to develop ND081, a potential first-in-class multi-specific antibody for the treatment of inflammatory bowel disease (IBD).

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : $14.6 million

                            November 15, 2024

                            Lead Product(s) : ND081

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Recipient : Numab Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Betahistine Dimesilate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Approved FDF

                            Recipient : Eisai

                            Deal Size : $25.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical

                            Details : Eisai divested its rights for Merislon (betahistine mesilate), used to treat Meniere's syndrome, and muscle relaxant Myonal (eperisone hydrochloride) in Japan to Kaken.

                            Product Name : Merislon

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 29, 2024

                            Lead Product(s) : Betahistine Dimesilate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Approved FDF

                            Recipient : Eisai

                            Deal Size : $25.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Seladelpar Lysine

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase III

                            Recipient : CymaBay Therapeutics

                            Deal Size : $162.4 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize ...

                            Details : Under the terms of the agreement, Kaken receives an exclusive license to develop, commercialize and market MBX-8025 (seladelpar), a first-in-class treatment for people with primary biliary cholangitis (PBC), in Japan for PBC.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $34.0 million

                            August 01, 2023

                            Lead Product(s) : Seladelpar Lysine

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase III

                            Recipient : CymaBay Therapeutics

                            Deal Size : $162.4 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NM26-2198

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Recipient : Numab Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program

                            Details : NM26-2198 is a bi-specific antibody which targets IL-4Rα (type I and type II receptors) and IL-31 for the treatment of moderate-to-severe atopic dermatitis (AD).

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 15, 2023

                            Lead Product(s) : NM26-2198

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Recipient : Numab Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : Spruce Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement t...

                            Details : SPR001 (tildacerfont) is a potent and highly selective, non-steroidal, oral antagonist of the corticotropin-releasing factor (CRF) 1 receptor. The CRF1 receptor is abundantly expressed in the pituitary gland where it is the primary regulator of the HPA a...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $15.0 million

                            May 01, 2023

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : Spruce Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth